Even if in humans, a vaccine targeting CD8+ T cells recognizing antigens presented by non-classical MHC class I molecules were able to provide protection from HIV infection, it would not necessarily rule out the possibility of manipulating standard CD4+ regulatory T cells to add to any benefit associated with CD8+ regulatory T cells. This evidence concerns the gene CD8A and HIV infectious disease.